Y-mAbs Therapeutics, Inc. (YMAB) earnings
YMAB earnings moved a median of -0.24% by the close. Quarterly and annual YMAB reports and results, each read against the price at its own news timestamp. Back to the YMAB overview →
22 measured YMAB earnings events.
Where these YMAB earnings landedvs 22 measured YMAB earnings reactions
| Middle 50% of YMAB earnings reactions | -6.13% to +0.94% |
|---|---|
| Median reaction (to close) | -0.24% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 YMAB earnings events with a measured close landed between -6.13% and +0.94%; 41% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Y-mAbs Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -0.06% | +0.00% | |
| Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments | Press release | -0.06% | +0.00% | |
| Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025 | Press release | +0.23% | +0.12% | |
| Form 10-Q Y-mAbs Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +6.70% | -7.14% | |
| Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments | Press release | +6.70% | -7.14% | |
| Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025 | Press release | +2.02% | -8.31% | |
| Form 10-K/A Y-mAbs Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -1.90% | -0.47% | |
| Form 10-K Y-mAbs Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +1.14% | +13.24% | |
| Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments | Press release | +1.14% | +13.24% | |
| Form 10-Q Y-mAbs Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -7.46% | +12.17% | |
| Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments | Press release | -7.46% | +12.17% | |
| Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast | Press release | +0.20% | -2.23% | |
| Form 10-Q Y-mAbs Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -10.75% | +0.91% | |
| Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments | Press release | -10.75% | +0.91% | |
| Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast | Press release | -1.34% | +2.68% | |
| Form 10-Q Y-mAbs Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -1.16% | -12.42% | |
| Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments | Press release | -1.16% | -12.42% | |
| Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024 | Press release | +1.39% | -1.41% | |
| Form 10-K Y-mAbs Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -4.73% | -8.52% | |
| Form 10-Q Y-mAbs Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -1.99% | -3.07% | |
| Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments | Press release | -1.99% | -3.07% | |
| Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023 | Press release | -0.57% | +0.94% |
Keep exploring
More YMAB: analyst actions → · SEC filings → · YMAB overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| GSRX INDUSTRIES INC (GSRX) | 226 | 0.00% | 19% |
| TETRALOGIC PHARMS CORP (TLOG) | 226 | +0.20% | 52% |
| Aurinia Pharmaceuticals Inc - Common Shares (AUPH) | 224 | +0.13% | 54% |
| Cel-Sci Corporation (CVM) | 224 | -0.54% | 37% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.